# Hydroxyurea in Treating Patients With Recurrent and/or Unresectable Meningioma

> **NCT00006119** · PHASE2 · COMPLETED · sponsor: **UNICANCER**

## Conditions studied

- Brain and Central Nervous System Tumors

## Interventions

- **DRUG:** hydroxyurea

## Key facts

- **NCT ID:** NCT00006119
- **Lead sponsor:** UNICANCER
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-07
- **Primary completion:** 2004-12
- **Final completion:** 2008-01
- **Target enrollment:** — (—)
- **Last updated:** 2021-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00006119

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00006119, "Hydroxyurea in Treating Patients With Recurrent and/or Unresectable Meningioma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00006119. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*